Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.
Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokin...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-06-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://doi.org/10.1371/journal.ppat.1010547 |
| _version_ | 1828403103496404992 |
|---|---|
| author | Daniel Clark Files Frank Tacke Alexandra O'Sullivan Patrick Dorr William G Ferguson William G Powderly |
| author_facet | Daniel Clark Files Frank Tacke Alexandra O'Sullivan Patrick Dorr William G Ferguson William G Powderly |
| author_sort | Daniel Clark Files |
| collection | DOAJ |
| description | Coronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes. |
| first_indexed | 2024-12-10T10:13:25Z |
| format | Article |
| id | doaj.art-1a96f9a38e594553b94d882c91ae3000 |
| institution | Directory Open Access Journal |
| issn | 1553-7366 1553-7374 |
| language | English |
| last_indexed | 2024-12-10T10:13:25Z |
| publishDate | 2022-06-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS Pathogens |
| spelling | doaj.art-1a96f9a38e594553b94d882c91ae30002022-12-22T01:53:04ZengPublic Library of Science (PLoS)PLoS Pathogens1553-73661553-73742022-06-01186e101054710.1371/journal.ppat.1010547Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19.Daniel Clark FilesFrank TackeAlexandra O'SullivanPatrick DorrWilliam G FergusonWilliam G PowderlyCoronavirus Disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has created a global pandemic infecting over 230 million people and costing millions of lives. Therapies to attenuate severe disease are desperately needed. Cenicriviroc (CVC), a C-C chemokine receptor type 5 (CCR5) and C-C chemokine receptor type 2 (CCR2) antagonist, an agent previously studied in advanced clinical trials for patients with HIV or nonalcoholic steatohepatitis (NASH), may have the potential to reduce respiratory and cardiovascular organ failures related to COVID-19. Inhibiting the CCR2 and CCR5 pathways could attenuate or prevent inflammation or fibrosis in both early and late stages of the disease and improve outcomes of COVID-19. Clinical trials using CVC either in addition to standard of care (SoC; e.g., dexamethasone) or in combination with other investigational agents in patients with COVID-19 are currently ongoing. These trials intend to leverage the anti-inflammatory actions of CVC for ameliorating the clinical course of COVID-19 and prevent complications. This article reviews the literature surrounding the CCR2 and CCR5 pathways, their proposed role in COVID-19, and the potential role of CVC to improve outcomes.https://doi.org/10.1371/journal.ppat.1010547 |
| spellingShingle | Daniel Clark Files Frank Tacke Alexandra O'Sullivan Patrick Dorr William G Ferguson William G Powderly Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. PLoS Pathogens |
| title | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
| title_full | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
| title_fullStr | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
| title_full_unstemmed | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
| title_short | Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19. |
| title_sort | rationale of using the dual chemokine receptor ccr2 ccr5 inhibitor cenicriviroc for the treatment of covid 19 |
| url | https://doi.org/10.1371/journal.ppat.1010547 |
| work_keys_str_mv | AT danielclarkfiles rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 AT franktacke rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 AT alexandraosullivan rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 AT patrickdorr rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 AT williamgferguson rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 AT williamgpowderly rationaleofusingthedualchemokinereceptorccr2ccr5inhibitorcenicrivirocforthetreatmentofcovid19 |